Clinical trial · Observational
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
NCT03017690CI-TRIAL-00036256completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastroenteropancreatic Neuroendocrine Tumor | Digestive System Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- lanreotide group (Somatuline Depot®)
- label
- octreotide LAR group (Sandostatin LAR®)
Primary outcomes (1)
- measure
- The total time for product preparation and administration
- timeFrame
- Day 1
- description
- Total drug delivery time
Secondary outcomes (5)
- measure
- Total patient wait time for administration
- timeFrame
- Day 1
- description
- For the purposes of this study, "total patient wait time" refers to the time the patient checks in at the infusion room until completion of drug administration and discharge of the patient from the infusion room.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women must be 18 years of age or older * A current diagnosis of advanced, unresectable GEP-NET * Provided written informed consent to participate in the study * Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA). Exclusion Criteria: * Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial * Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day * Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment * Known hypersensitivity to somatostatin analogues
References
Publications (1)
- DERIVEDRyan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, Favaro JP, Dranitsaris G. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. J Oncol Pharm Pract. 2019 Sep;25(6):1425-1433. doi: 10.1177/1078155219839458. Epub 2019 Mar 29. PMID 30924737